Back to Search
Start Over
Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy
- Source :
- Annals of Oncology. 30:v729
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Background Proper evaluation and management of chemotherapy-related toxicity (CRT) is critical to cancer patients. We aimed to assess the clinical utility of STAF in patients with breast cancer receiving chemotherapy. Methods The STAF is a systematic form including common CRT lists and grades to help clinicians to assess CRT comprehensively as opposed to assessing CRT individually by cases. Using data from clinical data warehouse, the CRT profile was analyzed in patients with breast cancer receiving adjuvant or neoadjuvant therapy during two time periods; before (n = 1874) and after (n = 981) using STAF in the clinic at Asan Medical Center. The two cohorts were matched by age and chemotherapy, leaving conventional practice (A; n = 333) and STAF (B; n = 333) groups. The rates of unscheduled hospital utilization (outpatient department [OPD], emergency room [ER] and hospitalization) were compared between group A and B. Results No significant differences were noted in baseline characteristics between the two groups, except for a higher proportion of patients living near the hospital in group A compared to group B (67.0 vs 56.2%; P = 0.004). The completion rate of planned chemotherapy was 96.7% and 97.6% (P = 0.704), and the rate of dose reduction was 12.3% and 10.8% (P = 0.473), respectively, in group A and B. The median dose intensity was lower in group A than group B (0.92 vs. 0.95; P Table . 1788P Unscheduled utilization since cycle 2 of chemotherapy Group A (n = 333, %) Group B (n = 333, %) P OPD 22 (6.6) 11 (3.3) 0.050 ER 56 (16.8) 32 (9.6) 0.006 Hospitalization 42 (12.6) 28 (8.4) 0.077 Conclusions Using the STAF may facilitate to capture CRT in clinical practice and reduce the rates of unscheduled hospital utilization in patients with breast cancer receiving adjuvant or neoadjuvant therapy. Legal entity responsible for the study The authors. Funding Korean Foundation for Cancer Research. Disclosure All authors have declared no conflicts of interest.
Details
- ISSN :
- 09237534
- Volume :
- 30
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi...........05556a89b13bc95519536b25f77c6e4a
- Full Text :
- https://doi.org/10.1093/annonc/mdz265.034